# RAG-Based ASCO-Style Scorecards (PubMed Context Only, LanceDB)

## Scorecard for: Enzalutamide Versus Placebo After Chemotherapy in Metastatic Adenocarcinoma of Prostate

**Scenario Hint Provided to LLM:** A trial of enzalutamide vs placebo in metastatic prostate cancer post-chemotherapy. Hypothesize plausible efficacy (OS/PFS) and common toxicities for this drug class in this setting. Consider potential for some bonus points.

Below is a plausible ASCO Value Framework scorecard for the trial “Enzalutamide Versus Placebo After Chemotherapy in Metastatic Adenocarcinoma of Prostate” based on a set of hypothesized inputs:

• Hypothesized primary endpoint HR (e.g., overall survival) = 0.75  
  • Clinical Benefit Score = (1 – 0.75) × 100 × 1 = 25

• Hypothesized Toxicity: Enzalutamide in this post‑chemotherapy mCRPC setting may show a modest increase in certain grade 3 adverse events (e.g., fatigue, hypertension) compared with placebo. Based on this difference, we assign a Toxicity Score of –5.

• Hypothesized Bonus Points (reflecting additional benefits such as a potential tail-of-the-curve effect, improved palliation, a longer Treatment-Free Interval, and enhanced health-related quality-of-life):  
  • Tail of the Curve: +5  
  • Palliation: +3  
  • Treatment-Free Interval: +2  
  • Health-related QoL: +3  
  • Total Bonus Points = 5 + 3 + 2 + 3 = 13

• Net Health Benefit (NHB) is the sum of the Clinical Benefit Score, Toxicity Score, plus Total Bonus Points:  
  NHB = 25 + (–5) + 13 = 33

• Cost Context: Enzalutamide is an advanced androgen receptor pathway inhibitor that tends to be high in acquisition cost. In this setting, the cost is considered high, though the value may be partly offset by the survival and quality-of-life benefits.

The complete scorecard is presented in the table below:

-----------------------------------------------------
| Measure                  | Result/Score                                                             |
|--------------------------|--------------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 – 0.75) × 100 × 1 = 25                                              |
| **Toxicity Score**        | –5 (Modest increase in grade 3 adverse events vs. placebo)              |
| **Bonus Points**          | Tail of the Curve: +5                                                  |
|                          | Palliation: +3                                                         |
|                          | Treatment-Free Interval: +2                                            |
|                          | Health-related QoL: +3                                                 |
| **Total Bonus Points**    | 5 + 3 + 2 + 3 = 13                                                     |
| **Net Health Benefit**    | 25 + (–5) + 13 = 33                                                    |
| **Cost**                  | High; advanced ARPI pricing with potential offset by improved outcomes |
-----------------------------------------------------

This hypothetical scorecard uses assumed values to illustrate a structured evaluation based on efficacy, toxicity, bonus considerations, and cost context.

---

## Scorecard for: Doxorubicin + Cyclophosphamide → Paclitaxel + Trastuzumab vs Doxorubicin + Cyclophosphamide + Paclitaxel in Adjuvant HER2+ Breast Cancer

**Scenario Hint Provided to LLM:** A trial comparing a trastuzumab-containing regimen (AC-TH type) with a non-trastuzumab chemo regimen (AC-T type) in adjuvant HER2+ breast cancer. Hypothesize impact of targeted therapy on efficacy. Toxicity might be similar or specific to trastuzumab.

Below is one example of an ASCO Value Framework style scorecard based on hypothesized inputs for the trial comparing a trastuzumab‐containing adjuvant regimen (AC-TH) versus a non-trastuzumab regimen (AC-T) in HER2‑positive breast cancer.

For this exercise we hypothesize:
• A plausible Hazard Ratio (HR) for the primary endpoint of 0.70 (i.e. a 30% relative improvement in the experimental arm).  
• Although overall chemotherapy toxicities are similar between the arms, the addition of trastuzumab brings a slightly higher risk for cardiac toxicity; overall we assign a net toxicity “penalty” of –5.  
• Hypothesized bonus points reflecting potential long‐term survival benefits (“tail of the curve”, +5), minimal palliation effect in a curative adjuvant setting (0), a modest improvement in treatment‐free intervals (+1), and improved health-related quality-of-life due to lower recurrence risk (+2). Total bonus points = +8.  
• Finally, though the trastuzumab-containing regimen comes at a higher acquisition cost (i.e. high cost context), the improved efficacy may help justify this cost.

The Calculation of the components is done as follows:
• Clinical Benefit Score = (1 – HR) * 100  
  = (1 – 0.70) * 100 = 30  
• Toxicity Score = –5 (reflecting a slight toxicity penalty driven by cardiac risks)  
• Total Bonus Points = 5 (Tail) + 0 (Palliation) + 1 (Treatment-Free Interval) + 2 (HRQoL) = 8  
• Net Health Benefit (NHB) = 30 (Clinical Benefit) + (–5) (Toxicity) + 8 (Bonuses) = 33

Below is the resulting scorecard presented in a markdown table:

---------------------------------------------------------------
| Measure                  | Result/Score                                                                                                     |
|--------------------------|------------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 – 0.70) * 100 * 1 = **30**                                                                                      |
| **Toxicity Score**         | Based on a slight increase in cardiac toxicity with trastuzumab → **–5**                                           |
| **Bonus Points**           | Tail of the Curve: **+5**                                                                                        |
|                          | Palliation: **0**                                                                                                |
|                          | Treatment-Free Interval: **+1**                                                                                   |
|                          | Health-related QoL: **+2**                                                                                        |
| **Total Bonus Points**     | 5 + 0 + 1 + 2 = **8**                                                                                            |
| **Net Health Benefit**     | 30 (CBS) + (–5) (TS) + 8 (Bonuses) = **33**                                                                        |
| **Cost**                 | Higher costs associated with targeted therapy (trastuzumab), justified by improved efficacy outcomes in HER2+ disease. |
---------------------------------------------------------------

This scorecard, based solely on the hypothesized values, illustrates a moderate net benefit of the experimental regimen when considering efficacy gains balanced against increased toxicity and higher cost.

---

## Scorecard for: Ipilimumab Versus Placebo After Primary Treatment of Stage III Melanoma

**Scenario Hint Provided to LLM:** A trial of ipilimumab vs placebo in the adjuvant setting for Stage III melanoma. Hypothesize plausible DFS benefit and significant immune-related toxicities common for older checkpoint inhibitors.

Below is a hypothetical ASCO Value Framework–style scorecard for the trial “Ipilimumab Versus Placebo After Primary Treatment of Stage III Melanoma” based on plausible inputs:

──────────────────────────────
Step 1. Hypothesized Key Inputs:
• Hypothesized Hazard Ratio (HR) for DFS (disease‐free survival): 0.80  
  → This implies a 20% relative improvement in DFS over placebo.
• Toxicity: Ipilimumab, as an older checkpoint inhibitor, is known for significant immune‐related adverse events.  
  → We hypothesize that the experimental arm incurs a notable toxicity “penalty” compared with placebo; we estimate an adverse impact equivalent to –12 points.
• Bonus Points (additional benefits beyond the primary endpoint):  
  – Tail of the Curve: +5 points (reflecting a subset of patients who may achieve sustained long‐term benefit)  
  – Palliation: 0 points (the adjuvant setting is not primarily about symptom palliation)  
  – Treatment-Free Interval: 0 points (the design does not emphasize treatment breaks)  
  – Health-related Quality of Life: +3 points (a modest improvement may be noted in long‐term survivorship despite toxicity)  
  → Total Bonus Points = 5 + 0 + 0 + 3 = +8 points.
• Cost Context: Ipilimumab is a high-cost therapy relative to placebo, bearing implications for affordability and value.
──────────────────────────────
Step 2. Calculation of Scorecard Components:
• Clinical Benefit Score = (1 − HR) × 100 × Factor  
  → Factor is assumed = 1  
  → Calculation: (1 – 0.80) × 100 = 20 points.
• Toxicity Score: Based on the hypothesized increased immune‐related toxicities in the ipilimumab arm, we assign a –12 point adjustment.
• Total Bonus Points: +8 points as detailed above.
• Net Health Benefit (NHB) = Clinical Benefit Score + Toxicity Score + Total Bonus Points  
  → Calculation: 20 + (–12) + 8 = 16 points.
──────────────────────────────
Step 3. Final ASCO Value Framework Scorecard:

| Measure                    | Result/Score                                                                                                |
|----------------------------|-------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 – 0.80) × 100 × 1 = **20 points**                                                                       |
| **Toxicity Score**         | Significant immune‐related toxicity in the ipilimumab arm → **–12 points**                                  |
| **Bonus Points**           | Tail of the Curve: +5 points                                                                              |
|                            | Palliation: 0 points                                                                                       |
|                            | Treatment-Free Interval: 0 points                                                                          |
|                            | Health-related QoL: +3 points                                                                               |
| **Total Bonus Points**     | 5 + 0 + 0 + 3 = **8 points**                                                                                 |
| **Net Health Benefit**     | 20 + (–12) + 8 = **16 points**                                                                               |
| **Cost**                 | High-cost therapy relative to placebo; reflects significant economic investment required in the adjuvant setting. |

──────────────────────────────
This hypothetical scorecard suggests that while ipilimumab in the adjuvant setting provides a moderate clinical benefit (20 points), the significant immune-related toxicity (–12 points) partially offsets this, and the bonus points from potential long-term survival improvements and HRQoL add additional value. The net health benefit comes to 16 points, set against a high cost framework.

---

## Scorecard for: Ibrutinib Versus Chlorambucil As Initial Therapy for Chronic Lymphocytic Leukemia

**Scenario Hint Provided to LLM:** A trial comparing ibrutinib (newer targeted therapy) against chlorambucil (older chemotherapy) as first-line treatment for CLL. Hypothesize significant efficacy benefit for ibrutinib but also its unique toxicity profile versus chlorambucil.

Below is a hypothetical ASCO Value Framework scorecard for the trial "Ibrutinib Versus Chlorambucil As Initial Therapy for Chronic Lymphocytic Leukemia" based on a reasoned set of assumptions:

─────────────────────────────────────────────  
Step 1. Hypothesized Key Inputs

• Hypothesized Hazard Ratio (HR) for Primary Endpoint: 0.60  
  • Rationale: Ibrutinib as a targeted therapy is expected to provide a significant improvement in efficacy versus chlorambucil, so a HR of 0.60 (i.e., a 40% relative risk reduction) is plausible.

• Hypothesized Toxicity Metrics:  
  • Ibrutinib, while offering considerable benefit, has a unique toxicity profile (e.g., risk of atrial fibrillation, bleeding) compared to the more conventional but less targeted chlorambucil; overall, the toxicity differential is modestly unfavorable for ibrutinib.  
  • For scoring purposes, we assign a Toxicity Score of –5.

• Hypothesized Bonus Points:  
  • Tail of the Curve: +5 (reflecting potential long-term survivors due to durable responses)  
  • Palliation: +3 (improvement in disease-related symptoms over the older chemotherapy option)  
  • Treatment-Free Interval: +2 (a possibility for extended time off treatment for some patients)  
  • Health-related Quality-of-Life (QoL): +4 (enhanced QoL seen with a targeted agent vs. traditional chemotherapy)  
  • Total Bonus Points: 5 + 3 + 2 + 4 = +14

• General Cost Context:  
  • Ibrutinib is a newer targeted therapy and is generally considerably more expensive than chlorambucil, which may impact cost-effectiveness discussions despite its clinical benefits.

─────────────────────────────────────────────  
Step 2. Calculate Scorecard Components  
• Clinical Benefit Score = (1 – Hypothesized HR) * 100 * Factor  
  = (1 – 0.60) * 100 * 1  
  = 0.40 * 100  
  = 40  
• Toxicity Score: –5 (reflecting the slight increased toxicity concerns with ibrutinib’s unique profile)  
• Total Bonus Points = +14  
• Net Health Benefit (NHB) = Clinical Benefit Score + Toxicity Score + Total Bonus Points  
  = 40 + (–5) + 14  
  = 49

─────────────────────────────────────────────  
Step 3. ASCO Value Framework Scorecard Table

| Measure                    | Result/Score                                                                                                  |
|----------------------------|---------------------------------------------------------------------------------------------------------------|
| **Clinical Benefit Score** | (1 - 0.60) * 100 * 1 = **40**                                                                                   |
| **Toxicity Score**         | Based on a modest increment in unique toxicities with ibrutinib vs. chlorambucil → **–5**                    |
| **Bonus Points**           | Tail of the Curve: +5                                                                                         |
|                            | Palliation: +3                                                                                                |
|                            | Treatment-Free Interval: +2                                                                                   |
|                            | Health-related QoL: +4                                                                                          |
| **Total Bonus Points**     | 5 + 3 + 2 + 4 = **+14**                                                                                         |
| **Net Health Benefit**     | 40 + (–5) + 14 = **49**                                                                                         |
| **Cost**                 | Ibrutinib is significantly more expensive than chlorambucil – high cost context impacting overall value.        |

─────────────────────────────────────────────  
This scorecard is hypothetical and based on assumed inputs reflecting significant efficacy gain with ibrutinib, a modest toxicity penalty due to its unique side effect profile, and bonus points reflecting improvements in long‐term outcomes and patient quality of life.

---

